Feature Type | Standardized | Nominal ANOVA | ||||
---|---|---|---|---|---|---|
mRNA | Bexarotene | FIMM | pan-cancer | AAC | -0.07 | 0.7 |
mRNA | Nilotinib | GDSC1000 | pan-cancer | AAC | 0.016 | 0.7 |
mRNA | Ki8751 | CTRPv2 | pan-cancer | AAC | 0.015 | 0.7 |
mRNA | XMD8-92 | GDSC1000 | pan-cancer | AAC | -0.021 | 0.7 |
mRNA | QW-BI-011 | CTRPv2 | pan-cancer | AAC | -0.029 | 0.7 |
mRNA | LAQ824 | GDSC1000 | pan-cancer | AAC | 0.015 | 0.7 |
mRNA | parbendazole | CTRPv2 | pan-cancer | AAC | -0.013 | 0.7 |
mRNA | salermide:PLX-4032 (12:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.016 | 0.7 |
mRNA | tivozanib | GDSC1000 | pan-cancer | AAC | 0.015 | 0.7 |
mRNA | GSK2636771 | CTRPv2 | pan-cancer | AAC | 0.018 | 0.7 |